Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | CPT2 | P23786 | 3/20 | 0.46 |
| ▸ | CPT1A | P50416 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 3/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777093 | 0.86 | OPRM1 (0.46) | HDAC1PRCPOPRM1OPRD1 | |
| SCHEMBL1777694 | 0.85 | CNR1 (0.45) | HDAC1PRCPHCRTR1HCRTR2 | |
| SCHEMBL1777866 | 0.83 | TRPV1 (0.47) | KCNH2TRPV1PRCPHCRTR1HCRTR2 | |
| SCHEMBL1778875 | 0.80 | KCNH2 (0.42) | KCNH2TRPV1CPT2CPT1AHDAC1 | |
| SCHEMBL1777469 | 0.80 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL4590434 | 0.79 | RAB9A (0.47) | HDAC1PRCP | |
| SCHEMBL1777666 | 0.79 | RAB9A (0.47) | HDAC1PRCP | |
| SCHEMBL5254777 | 0.79 | HDAC1 (0.39) | KCNH2TRPV1CPT2CPT1AHDAC1 | |
| SCHEMBL1776470 | 0.76 | RAB9A (0.46) | HDAC1PRCPHCRTR1HCRTR2 | |
| SCHEMBL1779471 | 0.76 | IDO1 (0.41) | HDAC1PRCPF11KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | KCNH2 827/4885TRPV1 94/4885CPT2 1127/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | KCNH2 948/4885TRPV1 73/4885CPT2 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.